Posts tagged Chardan


Bullish Sentiment In Akari Therapeutics PLC (ADR) (AKTX) Reverses; Chardan Sees 63% Downside for the Stock

After a 200% rally in less than a month, Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) shares tumbled nearly …

Chardan Bullish on AveXis Inc (AVXS) Following Rival Spinraza Broad-Label Approval

Chardan analyst Gbola Amusa is placing his confidence behind AveXis Inc (NASDAQ:AVXS) even in light …

Chardan Heads to Sidelines on Arrowhead Pharmaceuticals Inc (ARWR) Following RNAi Program Discontinuations

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) are currently plummeting 62% in pre-market trading after yesterday’s announcement that …

Biotech Beat: Analysts Share Two Cents on Amicus Therapeutics, Inc. (FOLD) and Synergy Pharmaceuticals Inc (SGYP)

Analysts are offering their two cents on biotech firms Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Synergy Pharmaceuticals …

Chardan Weighs in on Biotech Stocks Novavax, Inc. (NVAX) and Arrowhead Pharmaceuticals Inc (ARWR)

Chardan is divided when it comes to forecasts moving forward for biotech stocks Novavax, Inc. …

Analysts Speculate on Two Falling Biotech Stocks: Achillion Pharmaceuticals, Inc. (ACHN) and bluebird bio Inc (BLUE)

News from Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and bluebird bio Inc (NASDAQ:BLUE) have sent biotech investors …

Analysts Weigh in on Three Rising Healthcare Stocks: Palatin Technologies, Inc. (PTN), Novocure Ltd (NVCR) and AveXis Inc (AVXS)

Healthcare stocks Palatin Technologies (NYSEMKT:PTN), Novocure Ltd (NASDAQ:NVCR), and AveXis Inc (NASDAQ:AVXS) are reaping the benefits …

Chardan Bearish on Arbutus Biopharma Corp (ABUS) Following Clinical Update

In a research report released Friday, Chardan analyst Madhu Kumar reiterated a Sell rating on …

Here’s Why Valuation Around Esperion Therapeutics Inc (ESPR) May Remain Depressed: Chardan

In a research report issued today, Chardan analyst Gbola Amusa maintained a Sell rating on …

Here’s Why Chardan Reduced Price Target For Uniqure NV (QURE)

In a research note issued today, Chardan analyst Gbola Amusa maintained a Buy rating on shares …

Show More